Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + capecitabine + toripalimab with local radiotherapy for metastatic triple-negative breast cancer
ChiCTR2400091770Phase 2Recruiting
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib, capecitabine and toripalimab in triple-negative breast cancer (TNBC) and breast cancer, sponsored by Affiliated Hospital of North Sichuan Medical College. Primary endpoint: Objective Response Rate. Started Nov 2024; status: recruiting.
02
Drugs
anlotinibcapecitabinetoripalimab
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on ChiCTR2400091770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091770.